Table 3 Patient and tumour characteristics of metabolomics

Age(years)

 Median (range)

56 (37–80)

74 (58–82)

74 (46–88)

Baseline PSA (ng/mL)

 Median (range)

3.389 (0.41–14.7)

33.64 (6.66–284)

83.33 (22.86–101)

Post-treatment PSA (ng/ml)

 Median (range)

0.955 (0.01–37.33)

Gleason score, n (%)

   ≤ 6

4 (19.05%)

1 (7.69%)

  7

7 (33.33%)

1 (7.69%)

   ≥ 8

3 (14.29%)

3 (23.08%)

Local treatment, n (%)

 Radical Prostatectomy

6 (28.57%)

 Endocrinotherapy

9 (42.86%)